News
CEO of Novo Nordisk, maker of Wegovy, is stepping down
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price.
When considering a weight loss medication — or any medication — it’s normal to wonder when the effects will kick in.
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Everyday Health on MSN4d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...
A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...
One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
Axios on MSN2d
Wegovy maker Novo Nordisk CEO to step downNovo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its ...
The usual dose of Novo Nordisk’s expensive weight-loss drug Wegovy can be cut in half without affecting the results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback